[News] AACR Annual Meeting 2023

Jeffrey S Weber (NYU Langone Medical Center, New York, NY, USA) presented results from the randomised (2:1), open-label, phase 2 mRNA-4157-P201/KEYNOTE-942 trial in patients with completely resected high-risk melanoma. 107 patients received the intramuscular novel personalised cancer vaccine mRNA-4157 (1 mg every 3 weeks for nine doses) with intravenous pembrolizumab (200 mg every 3 weeks for up to 18 cycles) and 50 received pembrolizumab monotherapy. Median follow-up was 101 weeks in the combination group and 105 weeks in the monotherapy group.